.-In addition to the welldefined contribution of the liver, adipose tissue has been recognized as an important source of angiotensinogen (AGT). The purpose of this study was to define the angiotensin II (ANG II) receptors involved in regulation of adipose AGT and the relationship of this control to systemic AGT and/or angiotensin peptide concentrations. In LDL receptor-deficient (LDLR Ϫ/Ϫ ) male mice, adipose mRNA abundance of AGT was 68% of that in liver, and adipose mRNA abundance of the angiotensin type 1a (AT 1a) receptor (AT1aR) was 38% of that in liver, whereas mRNA abundance of the angiotensin type 2 (AT 2) receptor (AT2R) was 57% greater in adipose tissue than in liver. AGT and angiotensin peptide concentrations were decreased in plasma of AT 1aR-deficient (AT1aR Ϫ/Ϫ ) mice and were paralleled by reductions in AGT expression in liver. In contrast, adipose AGT mRNA abundance was unaltered in AT1aR Ϫ/Ϫ mice. AT 2 R Ϫ/Ϫ mice exhibited elevated plasma angiotensin peptide concentrations and marked elevations in adipose AGT and AT1aR mRNA abundance. Increases in adipose AGT mRNA abundance in AT2R Ϫ/Ϫ mice were abolished by losartan. In contrast, liver AGT and AT1aR mRNA abundance were unaltered in AT2R Ϫ/Ϫ mice. Infusion of ANG II for 28 days into LDLR Ϫ/Ϫ mice markedly increased adipose AGT and AT1aR mRNA but did not alter liver AGT and AT1aR mRNA. These results demonstrate that differential mRNA abundance of AT1a/AT2 receptors in adipose tissue vs. liver contributes to tissue-specific ANG II-mediated regulation of AGT. Chronic infusion of ANG II robustly stimulated AT1aR and AGT mRNA abundance in adipose tissue, suggesting that adipose tissue serves as a primary contributor to the activated systemic renin-angiotensin system. angiotensin II receptors; renin-angiotensin system; cardiovascular disease; obesity-related disorders; metabolic syndrome THE RENIN-ANGIOTENSIN SYSTEM (RAS) is well known to regulate blood pressure and fluid homeostasis. Activation of the RAS is a common feature in patients with the metabolic syndrome (47). Angiotensinogen (AGT), the only known precursor of angiotensin II (ANG II), is produced primarily by the liver (16). However, AGT mRNA is expressed by a variety of tissues. Thus, under different physiological/pathophysiological conditions, such as the metabolic syndrome, alternative tissues may contribute to the circulating AGT concentration. We previously demonstrated a high level of AGT mRNA expression in white and brown adipocytes (9, 10, 50, 56) . Moreover, expression of AGT in adipose tissue is nutritionally and hormonally regulated by obesity (3, 25, 48, 61) , insulin (30), fatty acids (49), and cAMP (55). Furthermore, previous studies demonstrated that transgenic overexpression of AGT in adipose tissue leads to its secretion into the circulation and rescues hypotension and leanness of AGT-deficient mice (43). These observations suggest that adipose-derived AGT can contribute to plasma AGT concentrations and may be involved in the pathogenesis of obesity-related diseases.
THE RENIN-ANGIOTENSIN SYSTEM (RAS) is well known to regulate blood pressure and fluid homeostasis. Activation of the RAS is a common feature in patients with the metabolic syndrome (47) . Angiotensinogen (AGT), the only known precursor of angiotensin II (ANG II), is produced primarily by the liver (16) . However, AGT mRNA is expressed by a variety of tissues. Thus, under different physiological/pathophysiological conditions, such as the metabolic syndrome, alternative tissues may contribute to the circulating AGT concentration. We previously demonstrated a high level of AGT mRNA expression in white and brown adipocytes (9, 10, 50, 56) . Moreover, expression of AGT in adipose tissue is nutritionally and hormonally regulated by obesity (3, 25, 48, 61) , insulin (30) , fatty acids (49) , and cAMP (55) . Furthermore, previous studies demonstrated that transgenic overexpression of AGT in adipose tissue leads to its secretion into the circulation and rescues hypotension and leanness of AGT-deficient mice (43) . These observations suggest that adipose-derived AGT can contribute to plasma AGT concentrations and may be involved in the pathogenesis of obesity-related diseases.
The RAS is considered to be a classical endocrine feedback regulatory system, exerting control over the synthesis and secretion of RAS components by end-product peptides. Wellrecognized sites for endocrine feedback regulation of the RAS by ANG II include AGT in the liver and renin in the kidney. ANG II positively regulates liver AGT mRNA expression and circulating AGT concentrations (33, 44) but negatively regulates kidney renin mRNA expression and release (52) . The significance of positive-and negative-feedback regulation by ANG II on RAS component expression differs across species. For example, in rats and humans, the predominant effect is to reduce further ANG II synthesis by suppression of renal synthesis and secretion of renin, the rate-limiting step in ANG II production (52) . In contrast, studies in mice suggest that AGT may limit the rate of production of systemic ANG II (11, 40) . Thus, in mice, ANG II may predominantly increase further peptide synthesis by increasing the concentration of circulating AGT. Feedback regulation of AGT and renin by ANG II is mediated primarily through the angiotensin type 1 (AT 1 ) receptor (AT 1 R) (34, 38) .
In contrast to endocrine feedback regulation by ANG II in tissues with well-documented roles in the synthesis of individual RAS components, less is understood regarding endocrine feedback regulation in alternative sites of expression that are recognized as important for local production of this peptide. Given that AT 1a Rs are expressed in mouse adipose tissue (5, 42) , we propose that ANG II exerts endocrine feedback regulation of AGT synthesis in adipocytes. Previously, we showed that the RAS is increased in hypercholesterolemic LDL receptor (LDLR)-deficient (LDLR Ϫ/Ϫ ) mice (13) . Therefore, in this study, we used LDLR Ϫ/Ϫ mice to attain a lipoprotein-cholesterol distribution that was more similar to that of humans. In addition, since our previous studies suggest that AGT may limit the rate of synthesis of ANG II in C57BL/6 mice (15), we used LDLR Ϫ/Ϫ mice with elevated systemic AGT to more closely mimic humans. We first compared RAS component expression of AGT, AT 1a R, and angiotensin type 2 (AT 2 ) receptors (AT 2 Rs) between adipose tissue and liver. We then determined the regulation of liver vs. adipose AGT and AT 1a R mRNA abundance in AT 1a R-and AT 2 R-deficient (AT 1a R Ϫ/Ϫ and AT 2 R Ϫ/Ϫ ) mice. Regulation of RAS expression in tissues was paralleled by measurement of plasma AGT and angiotensin peptide concentrations in mice with specific ANG II receptor deficiencies. Finally, we examined the effect of chronic ANG II infusion on adipose vs. liver AGT and AT 1a R expression.
MATERIALS AND METHODS

Mice and diet. LDLR
Ϫ/Ϫ male mice (B6.129S7-Ldlr tm1Her ; stock no. 002207) and AT1aR Ϫ/Ϫ male mice (B6.129P2-Agtr1a tm1Unc ; stock no. 002682) were obtained from the Jackson Laboratory. AT 2R Ϫ/y mice were a kind gift of Dr. T. Inagami (Vanderbilt University). All genotypes had been backcrossed 10 times into a C57BL/6 background. Littermates (LDLR Ϫ/Ϫ , AT1a ϫ LDLR Ϫ/Ϫ , and AT2 ϫ LDLR Ϫ/Ϫ ) were used for the present study. All mice were maintained in a barrier facility and fed normal mouse laboratory diet containing 5% fat, 20% protein, and 3.75 kcal/g digestible energy (diet no. 7012, Harlan Teklad, Madison, WI). All studies using animals were performed in accordance with American Association for Accreditation of Laboratory Animal Care "Guidelines for the Care and Use of Experimental Animals" and were approved by the Institutional Animal Care and Use Committee at the University of Kentucky.
Genotyping by PCR. For AT 1aR genotyping, the following primers were used: 5Ј-AAATGGCCCTTAACTCTTCTACTG-3Ј (antisense) and 5Ј-ATTAGGAAAGGGAACAGGAAGC-3Ј (sense). Resultant wildtype and deficient allele bands were 650 bp and 1.1 kb, respectively. For AT 2R genotyping, the following primers were used: 5Ј-GTAA-GAATTTGGAGTTGCTG-3Ј(sense) and 5Ј-GGGATTCCTTCTTT-GAGAC-3Ј (antisense). Resultant wild-type and deficient allele bands were 500 bp and 1.1 kb, respectively. For LDLR genotyping, the following primers were used: 5Ј-AGGTGAGATGACAGGAGATC-3Ј, 5Ј-AGGATGACTTCCGATGCCAG-3Ј, and 5Ј-GCAGTGCTC-CTCATCTGACTTG-3Ј. Resultant wild-type and deficient allele bands were 383 and 800 bp, respectively.
Total RNA isolation and reverse transcriptase PCR. Total RNA was extracted from mouse epididymal adipose tissue and liver using the SV total RNA isolation system (Promega, Madison, WI) according to the protocol provided by the manufacturer. Extracted RNAs were suspended in ribonuclease-free water and quantified by measurement of absorbance at 260 nm.
The abundance of mRNA in mouse adipose tissue and liver was estimated by real-time PCR using an iCycler (Bio-Rad), and the threshold cycle number was determined using iCycler software version 3.0. Real-time PCR product accumulation was monitored using the intercalating dye SYBR Green I, which exhibits a higher fluorescence on the binding of double-stranded DNA. The relative abundance of each mRNA was estimated using a standard curve constructed from serial dilutions of control cDNA. The mRNA abundance was calculated as the ratio of the gene of interest to 18S rRNA. Nontemplate control and non-RT control were used as a negative control. The real-time PCR was performed using the primers shown in Table 1 .
Administration of losartan or ANG II. Osmotic minipumps (model 2001 Alzet, Durect, Cupertino, CA) were implanted into 6-to 8-wkold LDLR Ϫ/Ϫ male mice (5 mice/group). Pumps were filled with saline vehicle or solutions of losartan (catalog no. L-158086-005H067, Merck) that delivered 30 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 for 7 days. Losartan, an AT1R-specific antagonist (58) , was used at a dose that previously afforded AT1R blockade (14) . For ANG II infusion studies, saline or ANG II (500 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was infused by osmotic minipump (model 2004) for 28 days. Pumps were placed in the subcutaneous space of ketamine-xylazine (50 and 5 mg/kg, respectively, ip)-anesthetized mice through a small incision in the flank of the neck, which was closed with surgical glue.
Western blotting analysis of AGT. As described previously (15), a chicken antibody was developed against mouse AGT. The sequence (EEEQPTTSVQPGSPE) used to generate the antibody was from the carboxyl terminus of AGT and did not react with other angiotensin peptides.
Mouse plasma samples were resolved electrophoretically, transferred to polyvinylidene difluoride membranes, and analyzed by Western blot as described elsewhere (37) . Polyvinylidene difluoride membranes were incubated with chicken anti-mouse AGT IgY (1: 500 -1:1,000 dilution in Tris-buffered saline with 5% nonfat dry milk and 0.1% Tween 20) and then with a peroxidase-conjugated rabbit anti-chicken IgY (1:5,000 -1:10,000 dilution; Jackson Immuno-Research). The immunoreactivity was visualized with an enhanced chemiluminescence Western blotting detection kit (Pierce, Rockford, IL). Kodak Image (Image Station, 440CF) was used for quantitative assessment of band densities.
Measurement of angiotensin peptides. Angiotensin peptides were resolved by HPLC as described previously (15) . HPLC fractions were assayed using an anti-ANG II antibody that exhibited 100% crossreactivity to ANG III and ANG-(3-8) (ANG IV) and 80% reactivity to ANG-(4 -8).
Statistical analysis. Values are means Ϯ SE. Statistical significance between groups was assessed by an unpaired t-test (Bonferroni/Dunn) Fig. 3 . Effect of AT1aR deficiency on plasma AGT (A) and angiotensin peptide (B) concentrations. Densitometric analysis of plasma AGT protein bands demonstrates a significant decrease in levels of 52-and 64-kDa AGT protein bands in AT1aR Ϫ/Ϫ mice. Plasma concentrations of angiotensin peptides were significantly decreased in AT1aR Ϫ/Ϫ mice, resulting in a marked reduction in the sum concentration of plasma angiotensins. Values are means Ϯ SE (n ϭ 4 -6 mice/group). *P Ͻ 0.05.
or by ANOVA using SigmaStat version 3.0. Data sets were tested to ensure that they complied with the constraints of parametric tests. P Ͻ 0.05 was considered statistically significant.
RESULTS
Differential expression of components of the RAS in adipose tissue vs. liver. We initially determined AGT, AT 1a R, angiotensin type 1b (AT 1b ) receptor (AT 1b R), and AT 2 R mRNA abundance in epididymal adipose tissue compared with liver of LDLR Ϫ/Ϫ mice. Adipose mRNA abundance of AGT was 68% of that in liver (Fig. 1A) . In mouse adipose tissue and liver, we detected AT 1a R and AT 2 R, but not AT 1b R mRNA (data not shown). AT 1a R mRNA expression was lower (2-fold) in adipose tissue than in liver (Fig. 1B) , whereas AT 2 R mRNA expression was 57% greater in adipose tissue than in liver (Fig. 1C) .
Effects of AT 1a R deficiency on adipose tissue, liver, and systemic RAS. To evaluate the effects of endocrine feedback regulation by ANG II on the RAS, we determined the effects of AT 1a R deficiency on the mRNA abundance of the AT 2 R and AGT in adipose tissue and liver. AT 2 R mRNA abundance was not altered in adipose tissue from AT 1a R Ϫ/Ϫ mice (AT 2 R-to-18S rRNA ratio ϭ 0.29 Ϯ 0.13 and 0.27 Ϯ 0.11 in AT 1a R ϩ/ϩ and AT 1a R Ϫ/Ϫ mice, respectively, P ϭ 0.929). Similarly, adipose mRNA abundance of AGT was unaltered in AT 1a R Ϫ/Ϫ mice ( Fig. 2A) . In contrast, liver AGT mRNA abundance was decreased (by 38%) in AT 1a R Ϫ/Ϫ mice (Fig. 2B) . Plasma AGT exhibited two protein bands (52 and 64 kDa), both of which were decreased (2-fold) in AT 1a R Ϫ/Ϫ mice (Fig. 3A) . To determine whether differential glycosylation gave rise to the two AGT protein bands (37, 41), we incubated plasma with peptide N-glycosidase F, which resulted in a single ϳ50-kDa protein AGT band (data not shown). Reductions in plasma AGT concentrations were accompanied by a decrease in angiotensin peptide concentrations in plasma of AT 1a R Ϫ/Ϫ mice (Fig. 3B) .
Effects of AT 2 R deficiency on adipose and systemic RAS. Adipose tissue from AT 2 R Ϫ/Ϫ mice exhibited increased AGT (by 63%; Fig. 4A ) and AT 1a R (by 83%; Fig. 4B ) mRNA abundance. In contrast, liver AGT mRNA abundance was unaltered by AT 2 R deficiency (data not shown). Elevations in adipose expression of these RAS components were accompanied by an increase in plasma concentrations of angiotensin peptides (Fig. 4C) . To determine whether these elevated angiotensin peptide concentrations contributed to enhanced RAS expression in adipose tissue through the AT 1a R, we administered losartan to AT 2 R ϩ/y and AT 2 R Ϫ/y mice. Elevations in the mRNA abundance of AGT and AT 1a R in adipose tissue were totally ablated in losartan-infused mice (Fig. 4, A and B) . Similar to results obtained in AT 1a R Ϫ/Ϫ mice, losartan administration decreased AGT mRNA abundance (by 53%) in the liver of AT 2 R Ϫ/y and AT 2 R ϩ/y mice. Adipose AGT and AT 1a R mRNA are increased by infusion of ANG II and paralleled by an increase in systemic AGT protein.
Results described above suggest that elevated systemic angiotensin peptide concentrations stimulate the adipose RAS. We infused LDLR Ϫ/Ϫ mice with ANG II at a dose that has been demonstrated to increase blood pressure (32) . Infusion of ANG II did not change AT 2 R mRNA expression in epididymal adipose tissue (AT 2 R-to-18S rRNA ratio ϭ 0.14 Ϯ 0.01 and 0.18 Ϯ 0.02 in saline-and ANG II-infused animals, respectively, P ϭ 0.07). However, infusion of ANG II resulted in a striking increase in the abundance of AT 1a R (7.3-fold) and AGT (2.8-fold) mRNA in adipose tissue (Fig. 5) . In contrast, there was no effect of ANG II infusion on liver AGT and AT 1a R mRNA expression (Fig. 5) . Plasma AGT concentrations (64-kDa band) were increased (2-fold) by ANG II infusion (Fig. 6) .
DISCUSSION
Our results demonstrate differential endocrine feedback regulation of the RAS in adipose tissue vs. liver. Mechanisms contributing to these effects include differences in AT 1a R vs. AT 2 R expression between adipose tissue and liver and differences in the ability of systemic ANG II to regulate AT 1a R expression in adipose tissue compared with liver. In AT 1a R Ϫ/Ϫ mice, we found that AGT protein concentrations in plasma parallel the mRNA abundance in liver. This suggests that AT 1a R-mediated regulation of AGT in mouse liver serves a primary role in determining the circulating AGT and ANG II concentrations. Results from AT 2 R
Ϫ/Ϫ mice demonstrate that a primary mediator of differential regulation of AGT by ANG II in liver vs. adipose tissue relates to expression of the AT 2 R in adipose tissue. In AT 2 R Ϫ/Ϫ mice, adipose expression of the AT 1a R and AGT paralleled plasma angiotensin peptide concentrations. Interestingly, in states of elevated systemic ANG II, marked elevations in AT 1a R expression in adipose tissue resulted in pronounced regulation of AGT in adipose tissue, but not in liver. These results suggest that adipose tissue contributes to the concentration of plasma AGT and/or ANG II under conditions of high systemic ANG II.
Tissue-specific regulation of the AT 1a R by ANG II. Previous studies have reported elevations in AT 1a R mRNA expression in a tissue-specific manner in states of elevated systemic ANG II, such as low salt, chronic ANG II infusion, and renovascular hypertension (17, 18, 29, 45, 53) . However, regulation of AT 1a R expression by ANG II has not been examined in adipose tissue. Our results extend previous findings by demonstrating a robust effect of ANG II to increase AT 1a R mRNA abundance in adipose tissue. In this study, a physiological consequence of ANG II regulation of AT 1a R expression in adipose tissue was the promotion of AGT expression. However, ANG II has been demonstrated to exert a variety of AT 1 R-mediated effects at adipocytes (8, 57, 59, 60) . Thus upregulation of AT 1a R mRNA in adipose tissue in states associated with high plasma ANG II concentrations could result in changes in a variety of adipocyte functions. In contrast to findings in adipose tissue, our results do not support regulation of liver AT 1a R expression after chronic ANG II infusion. These results are in agreement with previous data demonstrating no change in liver AT 1a R gene expression with ANG II infusion (29) . The relatively high mRNA abundance of the AT 1a R in liver vs. adipose tissue may have contributed to differences in the ability of ANG II to upregulate AT 1a R expression between these tissues.
No studies have examined differential expression of upstream transcriptional binding partners in adipose tissue vs. liver. The AT 1a promoter exhibits a high degree of complexity in its regulation, and certain polymorphisms are thought to be associated with differential regulation of this receptor (12) . The transcription factor Sp1 associates with a Ϫ98/Ϫ79 and Ϫ58/Ϫ34 region sequence (GC-rich) of the AT 1a R promoter in A10 smooth muscle cells and a human trophoblast cell line (19, 36) . Expression of the AT 1a R is induced by ANG II in vascular smooth muscle cells but is inhibited in the adrenal gland (12) . However, no studies have specifically examined whether liver and/or adipose tissue AT 1a R is associated with regulation by Sp1. Furthermore, a negative cis-regulatory element between Ϫ489 and Ϫ331 on the AT 1a R promoter was identified in PC-12 cells and rat brain, but not in liver (46) . These results suggest possible tissue-specific regulation of the AT 1a R via different transcription factors. Alternatively, cross talk between the AT 1a R and the AT 2 R in adipose tissue, but not in liver, may have influenced differential ANG II regulation of AT 1a R expression between these tissues.
Tissue-specific regulation of AGT by ANG II. Adipose tissue has been demonstrated to express the majority of components required for the synthesis of ANG II (7, 22) . Of these, AGT has been consistently demonstrated at a high level of expression in mouse (23, 35, 39, 50) , rat (3, 27) , and human (25, 26, 61) adipocytes. Previous investigators have demonstrated a variety of factors that regulate adipose AGT expression (1-3, 6, 10, 23, 24, 31, 35, 39, 49, 54, 55) . In contrast, relatively few studies have examined endocrine feedback regulation of adipose-derived AGT by angiotensin peptides. ANG II was reported to decrease AGT expression in differentiating human preadipocytes (51) but had no effect when incubated with primary mammary adipocytes (28) . Similar to responses observed in primary mammary adipocytes, we did not observe alterations in AGT mRNA expression in adipose tissue of AT 1a R Ϫ/Ϫ mice. In contrast, our results demonstrate robust regulation of AGT expression in adipose tissue of AT 2 R Ϫ/Ϫ mice. It is conceivable that the AT 2 R, by providing a competing site for ANG II binding in adipocytes, may have reduced the availability of ANG II to occupy the AT 1a R and, subsequently, regulate AGT expression. In support of this conclusion, the infusion of ANG II, which would elevate systemic ANG II concentrations at adipocytes and afford greater AT 1a R occupation, resulted in an upregulation of AT 1a R and AGT mRNA expression in adipocytes.
Taken together, our results demonstrate that in the presence of low or normal concentrations of plasma ANG II, the AT 1a R is not a primary mediator of AGT regulation in adipose tissue. In contrast, the AT 1a R is a primary regulator of AGT by ANG II in liver under these circumstances. In contrast, when AT 2 R expression is reduced in adipose tissue or in a situation of elevated systemic ANG II, our results support a primary role for AT 1a Rs in the regulation of adipose AGT expression.
Relationship between adipose and liver AGT regulation and systemic ANG II. Under most physiological conditions, ANG II generation is largely dependent on ANG I cleavage by renin, the rate-limiting enzyme in the generation of systemic ANG II. However, in most species, the Michaelis-Menten constant for renin approximates the plasma AGT concentration, suggesting that alterations in circulating AGT can influence ANG II synthesis (20) . In mice, several lines of evidence suggest that AGT may limit the rate of ANG II synthesis. Graded doses of sheep AGT resulted in a dose-dependent increase in blood pressure in mice, but not in rats, suggesting that AGT was limiting in mouse plasma (40) . Similarly, a dose-dependent increase in blood pressure was observed in mice treated with increasing doses of intravenously infused AGT, coincident with an elevation in systemic ANG II concentrations (11) . Collectively, these results suggest that regulation of AGT may serve as a primary mechanism for control of angiotensin peptide concentrations in mice.
Our findings demonstrate that liver AGT mRNA expression paralleled angiotensin peptide concentrations in AT 1a R Ϫ/Ϫ mice, supporting an important role of liver-derived AGT in the production of systemic ANG II. Interestingly, in AT 2 R Ϫ/Ϫ mice, the plasma concentrations of angiotensin peptides began to parallel AGT expression in adipose tissue, but not in liver. A primary mechanism for this effect was a striking increase in AT 1a R mRNA expression in adipose tissue of AT 2 R Ϫ/Ϫ mice. The ability of adipose tissue to contribute to AGT in plasma has been suggested from studies in transgenic mice overexpressing AGT in adipose tissue. These mice exhibit elevations in circulating concentrations of AGT and blood pressure (43) . Results from our studies extend these findings by demonstrating that marked upregulation of AT 1a R mRNA expression by ANG II makes adipose tissue a more prominent contributor to circulating AGT concentrations and, thereby, ANG II concentrations. In addition, these results demonstrate that ANG II can modulate adipose-derived AGT in a positive endocrine feedback loop through effects at the AT 1a R. Thus, under conditions of elevated systemic ANG II, our results would suggest that adipose tissue becomes a prominent source of AGT. We previously reported that diet-induced obesity in rats was associated with increased adipose AGT mRNA expression that correlated positively to plasma angiotensin peptide concentrations and blood pressure (3) . Interestingly, liver AGT expression was not altered in obese rats, suggesting that adipose tissue contributed significantly to systemic AGT/angiotensin concentrations. Recent studies suggest that reductions in body weight in obese patients were associated with decreased plasma AGT concentration, which correlated to waist circumference (21) . The positive-feedback endocrine regulation of adipose-derived AGT by ANG II demonstrated in this study may contribute to overactivity of the RAS in obesity-associated disorders.
In conclusion, results from this study demonstrate that adipose tissue differs from liver in the regulation of AGT by ANG II because of differences in the AT 1a R/AT 2 R populations of these tissues. Expression of the AT 2 R in mouse adipose tissue masks the effects of ANG II to increase AGT expression through the AT 1a R. When AT 2 Rs are ablated, plasma concentrations of ANG II begin to parallel AGT expression in adipose tissue, and not in liver. In addition, chronic infusion of ANG II resulted in marked upregulation of AT 1a R and AGT mRNA expression in adipose tissue, but not in liver. In ANG II-infused mice, plasma AGT concentrations paralleled adipose AGT mRNA expression. These results demonstrate that ANG II regulates adipose AGT via activation of the AT 1a R and that this positive-feedback loop may play an important role in the pathogenesis of ANG II-related cardiovascular diseases.
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